Guyuan Medical Secures Tens of Millions of RMB in Series A Funding to Build a Global Leading Integrated Solution Provider for Medical Devices and Consumables

VCBeat has learned at the earliest opportunity that a medical polymer materials technology enterpriseShenzhen GuYuan Plastic Produce Co., Ltd. (hereinafter referred to as "GuYuan Medical")Completed recentlyTens of Millions in Series A FundingFinancing. This marks capital recognition and support received just half a year later. This round of financing was led byGuiyang Venture CapitalInvestment,Zhijin CapitalContinue to serve as the long-term exclusive financial advisor to GuYuan Medical. The funds from this round will be used for the construction of new production lines for medical materials and medical consumables.

Guoyuan Medical, established in 2005, is a leading domestic provider of comprehensive solutions for medical devices and consumables. The company has built an end-to-end solution covering precision mold design and manufacturing, R&D of medical-grade polymer materials, and lean production of medical consumables and structural components for medical devices. It holds a dominant technological edge and market position in fields such as in vitro diagnostics, medical imaging, and life support. Guoyuan Medical has become a core supplier to many top-tier Chinese healthcare enterprises, including Mindray Medical, New Industries Biomedical Engineering, YHLO, and BGI Genomics.

Over the past two years, China’s healthcare industry has been impacted by anti-corruption campaigns and centralized volume-based procurement. While these developments have superficially intensified hyper-competition among manufacturers, they have in fact accelerated the market exit of products with low technological barriers and low value-added content. Industrial value is increasingly concentrating on leading enterprises that possess advantages in products, technology, and services.

Among these, medical consumables and medical-grade polymer materials, as critical upstream products and core raw materials for the in vitro diagnostics (IVD) and life sciences industries, embody extensive scientific research achievements and accumulated manufacturing expertise, constituting a pivotal segment of the industry chain. According to Frost & Sullivan projections, the global market size for medical polymer-based consumables is expected to exceed USD 60 billion by 2030.

Leveraging its strong core competitiveness and resilience, GuYuan Medical has become one of the few medical device and consumable suppliers to achieve counter-trend growth, further consolidating its leading market position.

Backed by a team of polymer material experts from Sichuan University, GuYuan Medical’s new materials division achieved a major breakthrough in upstream medical-grade polymers in just eight months in 2023, going from zero to one. The newly developed material for high-pressure contrast injectors helped clients overcome production bottlenecks and reduce material costs, replacing their previously imported suppliers.

In 2024, the new materials team at Guyuan Medical made significant advances in high-value consumables such as angiographic catheters and microfluidics. Its self-developed new material products have gained high recognition from customers, demonstrating the feasibility of domestic substitution for high-end medical polymer materials through technical solutions.

Furthermore, GuYuan Medical has established robust industry-academia-research collaboration mechanisms with prestigious universities such as Sichuan University and Sun Yat-sen University, jointly exploring cutting-edge research and industrialization initiatives in medical polymer materials to empower partners in the healthcare industry.

Guoyuan Medical has established an excellent reputation for quality within the industry, repeatedly earning the title of “Outstanding Supplier” from Mindray Medical due to its outstanding delivery stability. In recent years, as its customers have expanded their overseas presence, Guoyuan Medical has leveraged its superior delivery quality to follow them into markets across Southeast Asia, Africa, South America, and other regions worldwide.

At the end of 2023, Guyuan Medical announced its brand internationalization and globalization strategy, making 2024 the inaugural year of its independent global expansion. During this period, Guyuan Medical’s product solutions were procured by top-50 global medical device companies. By simultaneously expanding its brand influence and enhancing internal management capabilities, Guyuan Medical has strengthened its international presence and is steadily evolving into a world-class brand through superior quality, faster response times, and enhanced service.

Guiyang Venture Capitalstated: “GuYuan Medical has been dedicated to the medical field for many years, with technical capabilities covering the entire process of polymer material development, precision mold design and manufacturing, and product design and production. The company boasts an excellent customer structure and serves as a core supplier to Mindray Medical, Snibe Diagnostics, and others. Its R&D and production of gene sequencing cassettes feature high technological barriers, making it an exclusive domestic product. We look forward to GuYuan Medical achieving new progress in its polymer materials business and overseas operations in the future.”

Lin Zhuowei, Vice President of Investment at Zhijin CapitalIt stated: “As a leading comprehensive solutions provider of medical devices and consumables in China, GuYuan Medical continues to evolve and deliver surprises. The company has successfully expanded upstream into the R&D and manufacturing of medical-grade polymer materials. By launching innovative material products that directly address industry pain points—such as catheter-grade TPU, clean-room TPE, and toughened PET—GuYuan Medical has extended its reach into broader and more cutting-edge application scenarios.”

Xin Shuangqi, Partner at Zhijin Capitalstated, “The challenges currently facing the healthcare industry present a significant opportunity for GuYuan Medical, which remains committed to deepening its industry expertise and consistently delivering above-expectation value to customers. Zhijin Capital is delighted to have once again assisted GuYuan Medical in successfully completing an equity financing round within six months. We will continue to partner with GuYuan Medical on its journey forward and witness the company achieve more milestones.”

Guiyang Venture Capital is a venture capital investment enterprise approved by the Guiyang Municipal People's Government. Established in December 2010, the company focuses on the sectors of healthcare and wellness, advanced equipment manufacturing, big data and electronic information, as well as new energy and new materials. It supports small and medium-sized enterprises (SMEs) with unique advantages during their start-up and growth stages to accelerate their development, aiming to serve as an incubator and catalyst for entrepreneurial ventures.

Zhijin Capital was established in 2015, evolving from a technology-focused angel investment firm into a professional financial advisory institution for the tech industry and the preferred industrial empowerment partner for entrepreneurs. Zhijin Capital has long focused on the advanced manufacturing sector, adhering to in-depth industry research and empowering technological innovation enterprises through a comprehensive approach combining “industrial resources + government resources + equity financing.” Since its inception, Zhijin Capital has assisted nearly 100 companies in successfully completing multiple rounds of equity financing. It serves as a council member unit of the Shenzhen Sensor Association and has received honors such as being ranked among China’s “Top 10 Advanced Manufacturing and High-Tech Industries” by Zero2IPO (CVSource).